Citations

Clear

7552 citation(s) found for "Ho, Matthew".

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
Rhee, Frits van , Voorhees, Peter M. , Srkalović, Gordan , Ide, Makoto , Munshi, Nikhil C. , Schey, Stephen, Streetly, Matthew , Pierson, Sheila K. , Partridge, Helen , Shilling, Dustin, Stone, Katie , Greenway, Amy D, Ruth, Jason R., Lechowicz, Mary Jo , Jayanthan, Raj , Leitch, Heather A. , Pemmaraju, Naveen , Chadburn, Amy , Lim, Megan S. , Elenitoba‐Johnson, Kojo S.J. , Goodman, Aaron M. , Hoffmann, Christian , Zinzani, Pier Luigi , Ferrero, Simone , Terriou, Louis , Simpson, David , Rossi, Jean‐François, Yoshizaki, Kazuyuki , Oksenhendler, Éric , van Rhee, Frits , Wong, Raymond S M , Casper, Corey , Fajgenbaum, David C , Ferrero, Simone , Zinzani, Pier Luigi , Dispenzieri, Angela , Fosså, Alexander , Partridge, Helen L., Mukherjee, Sudipto , Chandrakasan, Shanmuganathan , Jaffe, Elaine S. , Krymskaya, Vera P. , Sato, Yasuharu , Wong, Raymond , Rossi, Jean‐François , Nasta, Sunita , Kurzrock, Razelle , Uldrick, Thomas S. , Casper, Corey , Fajgenbaum, David C. , Ide, Makoto , Lim, Megan S

Mayo Clinic

Blood | September 4, 2018 | Volume: 132 | Issue: 20 | Pages: 2115-2124

10.1182/blood-2018-07-862334 | PMID 30181172 Get It

Abstract Castleman disease (CD) describes a group of heterogeneous hematologic disorders with characteristic histopathological features. CD can present with unicentric or multicentric (MCD) regions of lymph node enlargement. Some cases of MCD are caused by human herpesvirus-8 (HHV-8), whereas others are HHV-8–negative/idiopathic (iMCD). Treatment of iMCD is challenging, and outcomes can be poor because no uniform treatment guidelines exist, few systematic studies have been conducted, and no agreed upon response criteria have been described. The purpose of this paper is to establish consensus, evidence-based treatment guidelines based on the severity of iMCD to improve outcomes. An international Working Group of 42 experts from 10 countries was convened by the Castleman Disease Collaborative Network to establish consensus guidelines for the management of iMCD based on published literature, review of treatment effectiveness for 344 cases, and expert opinion. The anti–interleukin-6 monoclonal antibody siltuximab (or tocilizumab, if siltuximab is not available) with or without corticosteroids is the preferred first-line therapy for iMCD. In the most severe cases, adjuvant combination chemotherapy is recommended. Additional agents are recommended, tailored by disease severity, as second- and third-line therapies for treatment failures. Response criteria were formulated to facilitate the evaluation of treatment failure or success. These guidelines should help treating physicians to stratify patients based on disease severity in order to select the best available therapeutic option. An international registry for patients with CD (ACCELERATE, #NCT02817997) was established in October 2016 to collect patient outcomes to increase the evidence base for selection of therapies in the future.
A framework for quality measurement in the presurgical care of chronic rhinosinusitis: a review from the Quality Improvement Committee of the American Rhinologic Society
Mattos, José L. , Rudmik, Luke , Manes, Peter R., Lee, Jivianne, Schneider, John S. , Setzen, Michael, Parasher, Arjun K. , Smith, Timothy L. , Stokken, Janalee K., Stokken, Janalee K. , Smith, Timothy L , Carlson, Matthew L , Mattos, Jose , Soler, Zachary M. , Higgins, Thomas S , Lee, Jivianne T.

Mayo Clinic

International Forum of Allergy & Rhinology | September 3, 2018 | Volume: 8 | Issue: 12 | Pages: 1380-1388

10.1002/alr.22154 | PMID 30175899 Get It

BackgroundQuality improvement (QI) in the management of chronic rhinosinusitis (CRS) is garnering increasing attention. Defining frameworks and metrics to assess the quality of key components in CRS management could assist in reducing unwarranted practice variation and increase high‐quality care.MethodsA panel of the American Rhinologic Society (ARS) QI committee reviewed the literature to determine important presurgical components of CRS care that warrant QI. The evidence was organized into 4 categories: (1) diagnosis, (2) medical management, (3) appropriate patient selection for surgery, and (4) patient‐centered discussion. The combination of these categories was used to develop a framework termed the CRS Appropriate Presurgical Algorithm (CAPA).ResultsPrior to offering surgery for CRS, the best available evidence support the following quality metrics: (1) a guideline‐based diagnosis should be confirmed; (2) appropriate medical management, including a minimum of topical corticosteroid therapy and saline irrigations, should have been attempted (assuming patient tolerance); (3) a computed tomography (CT) scan should be obtained (to confirm the presence of sinus inflammation and for surgical planning); and (4) a patient‐centered discussion regarding treatment options for refractory CRS (ie, alternative medical therapies vs surgery vs observation) while focusing on risks and benefits, the need for long‐term medical compliance, and understanding of patient preferences and expectations.ConclusionDefining metrics that assess key components to CRS care prior to offering surgery has the potential to further improve upon an already successful treatment paradigm, reduce unwarranted practice variation, and to ensure that patients are receiving a similar level of high‐quality care.
Age-dependent effects of thoracic and capillary blood volume distribution on pulmonary artery pressure and lung diffusing capacity
Coffman, Kirsten E. , Boeker, Matthew G., Carlson, Alex R. , Johnson, Bruce D.

Mayo Clinic

Physiological Reports | September 2, 2018 | Volume: 6 | Issue: 17 | Pages: e13834

10.14814/phy2.13834 | PMID 30175463 Get It

Defining the Minimal Clinically Important Difference for Patients With Vestibular Schwannoma: Are all Quality-of-Life Scores Significant?
Kerezoudis, Panagiotis , Yost, Kathleen J. , Tombers, Nicole M. , Celda, María Peris, Carlson, Matthew L. , Link, Michael J.

Mayo Clinic

Neurosurgery | August 31, 2018 | Volume: 85 | Issue: 6 | Pages: 779-785

10.1093/neuros/nyy467 | PMID 30395303 Get It

Abstract BACKGROUND The diagnosis of vestibular schwannomas (VS) is associated with reduced patient quality of life (QOL). Minimal clinically important difference (MCID) was introduced as the lowest improvement in a patient-reported outcome (PRO) score discerned as significant by the patient. We formerly presented an MCID for the Penn Acoustic Neuroma QOL (PANQOL) battery based on cross-sectional data from 2 tertiary referral centers. OBJECTIVE To validate the PANQOL MCID values using prospective data. METHODS A prospective registry capturing QOL was queried, comprising patients treated at the authors’ institution and Acoustic Neuroma Association members. Anchor- and distribution-based techniques were utilized to determine the MCID for domain and total scores. We only included anchors with Spearman's correlation coefficient larger than 0.3 in the MCID threshold calculations. Most domains had multiple anchors with which to estimate the MCID. RESULTS A total of 1254 patients (mean age: 57.4 yr, 65% females) were analyzed. Anchor-based methods produced a span of MCID values (median, 25th-75th percentile) for each PANQOL domain and the total score: hearing (13.1, 13-16 points), balance (14, 14-19 points), pain (21, 20-28 points), face (25, 16-36 points), energy (16, 15-18 points), anxiety (16 [1 estimate]), general (13 [1 estimate]), and total (12.5, 10-15 points). CONCLUSION Current findings corroborate our formerly shared experience using multi-institutional, cross-sectional information. These MCID thresholds can serve as a pertinent outcome when deciphering the clinical magnitude of VS QOL endpoints in cross-sectional and longitudinal studies.
Recurrent desmoid-type fibromatosis associated with underlying neuromuscular choristoma
Stone, Jonathan J. , Prasad, Nikhil K. , Howe, B. Matthew, Amrami, Kimberly K. , Carter, Jodi M. , Jentoft, Mark E. , Spinner, Robert J. , Laumonerie, Pierre , Carter, Jodi

Mayo Clinic

Journal of Neurosurgery | August 31, 2018 | Volume: 131 | Issue: 1 | Pages: 175-183

10.3171/2018.3.jns152935 | PMID 30168738 Get It

OBJECTIVEDesmoid-type fibromatosis (DTF) presents a therapeutic dilemma. While lacking metastatic potential, it is a locally aggressive tumor with a strong propensity for occurrence near nerve(s) and recurrence following resection. In this study, the authors introduce the association of an occult neuromuscular choristoma (NMC) identified in patients with DTF.METHODSAfter experiencing a case of DTF found to have an occult NMC, the authors performed a retrospective database review of all other cases of biopsy-proven DTF involving the extremities or limb girdles in patients with available MRI data. Two musculoskeletal radiologists with expertise in peripheral nerve imaging reviewed the MRI studies of the eligible cases for evidence of previously unrecognized NMC.RESULTSThe initial case of a patient with an occult sciatic NMC is described. The database review yielded 40 patients with DTF—18 (45%) in the upper limb and 22 (55%) in the lower limb. Two cases (5%) had MRI findings of NMC associated with the DTF, one in the proximal sciatic nerve and the other in the proximal tibial and sural nerves.CONCLUSIONSThe coexistence of NMC may be under-recognized in a subset of patients with extremity DTF. This finding poses implications for DTF treatment and the likelihood of recurrence after resection or biopsy. Further study may reveal crucial links between the pathogenesis of NMC and DTF and offer novel therapeutic strategies.
Cardiac Risk of Noncardiac Surgery After Percutaneous Coronary Intervention With Second-Generation Drug-Eluting Stents
Hanson, Andrew C. , Rihal, Charanjit S. , Gulati, Rajiv , Bell, Malcolm R. , Nuttall, Gregory A. , Smith, Bradford B. , Warner, Matthew A. , Warner, Nafisseh S. , Smith, Mark M. , Rihal, Charanjit S.

Mayo Clinic

Anesthesia & Analgesia | August 31, 2018 | Volume: 128 | Issue: 4 | Pages: 621-628

10.1213/ane.0000000000003408 | PMID 30169404 Get It

BACKGROUND: Noncardiac surgery (NCS) following percutaneous coronary intervention (PCI) with stenting is sometimes associated with major adverse cardiac events (MACEs). Second-generation drug-eluting stents (DES) were developed to decrease the incidence of MACE seen with bare metal and first-generation DES. METHODS: The medical records of all adult patients who underwent second-generation DES placement between July 29, 2008 and July 28, 2011 followed by NCS between September 22, 2008 and July 1, 2013 were reviewed. All episodes of MACE following surgery were recorded. RESULTS: A total of 282 patients (74.8% male) were identified who underwent NCS after PCI with second-generation DES. MACE occurred in 15 patients (5.3%), including 11 deaths. The incidence of MACE changed significantly with time from PCI to NCS: 17.1%, 10.0%, 0.0%, and 3.1% for patients undergoing NCS at 0–90, 91–180, 181–365, and ≥366 days, respectively. Compared with those having NCS ≥366 days after PCI, the odds ratio for MACE (95% confidence interval) was 6.4 (1.9 to 21.3) at 0–90 days and 3.4 (0.8 to 15.3) at 91–180 days. Seven days prior to NCS, 146 (52%) patients were on dual antiplatelet therapy (DAPT), 106 (38%) were on aspirin, and 30 (11%) did not receive antiplatelet therapy. Excessive surgical bleeding occurred in 19 cases (6.7%). While observed bleeding rates were lowest in those not receiving antiplatelet therapy, there were no statistically significant differences based on the presence or absence of antiplatelet therapy (3% [1/30] for no antiplatelet therapy compared to 6% [6/106] for aspirin monotherapy and 8% [12/146] for DAPT; Fisher exact test: P = .655). CONCLUSIONS: The incidence of MACE in patients with second-generation DES undergoing NCS was 5.3% and was highest in the first 180 days following DES implantation. The rate of excessive surgical bleeding was 6.7% with the highest observed rate in those on DAPT. However, differences by the presence or absence of antiplatelet therapy were not significant, and future large observational studies will be necessary to further define bleeding risk with continued DAPT.
A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiologya
Binnicker, Matthew J. , Campbell, Sheldon , Chapin, Kimberle C. , Gilligan, Peter H., Gonzalez, Mark D. , Jerris, Robert C. , Kehl, Sue C., Patel, Robin , Pritt, Bobbi S. , Richter, Sandra S. , Robinson-Dunn, Barbara, Schwartzman, Joseph D., Snyder, James W. , Telford, Sam R. , Theel, Elitza S. , Thomson, Richard B., Weinstein, Melvin P., Yao, Joseph D. , Patel, Robin , Pritt, Bobbi S , Miller, J. Michael , Carroll, Karen C.

Mayo Clinic

Clinical Infectious Diseases | August 31, 2018 | Volume: 67 | Issue: 6 | Pages: 813-816

10.1093/cid/ciy584 | PMID 30169655 Get It

Abstract The critical nature of the microbiology laboratory in infectious disease diagnosis calls for a close, positive working relationship between the physician/advanced practice provider and the microbiologists who provide enormous value to the healthcare team. This document, developed by experts in laboratory and adult and pediatric clinical medicine, provides information on which tests are valuable and in which contexts, and on tests that add little or no value for diagnostic decisions. This document presents a system-based approach rather than specimen-based approach, and includes bloodstream and cardiovascular system infections, central nervous system infections, ocular infections, soft tissue infections of the head and neck, upper and lower respiratory infections, infections of the gastrointestinal tract, intra-abdominal infections, bone and joint infections, urinary tract infections, genital infections, and other skin and soft tissue infections; or into etiologic agent groups, including arthropod-borne infections, viral syndromes, and blood and tissue parasite infections. Each section contains introductory concepts, a summary of key points, and detailed tables that list suspected agents; the most reliable tests to order; the samples (and volumes) to collect in order of preference; specimen transport devices, procedures, times, and temperatures; and detailed notes on specific issues regarding the test methods, such as when tests are likely to require a specialized laboratory or have prolonged turnaround times. In addition, the pediatric needs of specimen management are also emphasized. There is intentional redundancy among the tables and sections, as many agents and assay choices overlap. The document is intended to serve as a guidance for physicians in choosing tests that will aid them to quickly and accurately diagnose infectious diseases in their patients.
P6473Is carotid plaque shear wave elastography a marker of plaque vulnerability? Association with cardiovascular events and duration of statin therapy
DeMarco, J. Kevin , Huston, John , Brinjikji, Waleed , Macedo, Túlio Augusto Alves , Dailey, Eric J. , Hagen, Mary E., Huang, Rongchong , Urban, Matthew W. , Macedo, T A, Pellikka, Patricia A. , Mulvagh, Sharon L.

Mayo Clinic

European Heart Journal | August 30, 2018 | Volume: 39 | Issue: suppl_1 | Pages: No page available

10.1093/eurheartj/ehy566.p6473 Get It

Genomewide association study reveals novel genetic loci associated with change in renal function in heart transplant recipients
Asleh, Rabea , Snipelisky, David , Hathcock, Matthew , Kremers, Walter K. , Liu, Duan , Batzler, Anthony , Jenkins, Gregory D. , Kushwaha, Sudhir S. , Pereira, Naveen L. , Jenkins, Gregory, Kushwaha, Sudhir, Asleh, Rabea , Kremers, Walter K , Liu, Duan

Mayo Clinic

Clinical Transplantation | August 30, 2018 | Volume: 32 | Issue: 10 | Pages: No page available

10.1111/ctr.13395 | PMID 30160337 Get It

AbstractBackgroundRenal dysfunction occurs commonly after heart transplantation (HTx) with wide inter‐individual variability but whether a genetic predisposition exists in these patients is unknown. Genomewide association studies (GWAS) have not been performed to assess the association of genetic variation with change in renal function after HTx.MethodsClinical and demographic data of patients who underwent HTx and provided blood samples and consent for genetic analysis were included. Genotyping was performed using Illumina Infinium Human CoreExome v1.0 analysis kit. A GWAS utilizing linear regression models was performed with estimated glomerular filtration rate (eGFR) at 1 year as the phenotype after adjusting for baseline eGFR prior to HTx and conversion from calcineurin inhibitor to sirolimus as primary immunosuppression therapy.ResultsA total of 251 HTx recipients were genotyped for 314,903 single nucleotide polymorphisms (SNPs). The mean (SD) age was 50 (12.5) years; most patients were of European origin (n = 243, 96.8%) and males (n = 179, 71.3%). After adjustment for potential confounders, two variants, rs17033285 (P = 4.3 × 10−7) and rs4917601 (P = 6.46 × 10−7), in a long non‐coding RNA (lncRNA) gene LINC01121 and a pseudogene BTBD7P2, were identified to have a significant association with change in GFR at 1 year after HTx.ConclusionsOur first of its kind GWAS demonstrates that genetic variation affects renal function after HTx independent of other risk factors. Agnostic genetic approaches such as these may lead to identification of novel biological pathways such as the role of lncRNAs in the development of renal dysfunction post‐HTx.
ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer
Tu, Xinyi , Kahila, Mohamed M. , Zhou, Qin , Yu, Jia , Wang, Liewei , Harmsen, William S. , Mutter, Robert W. , Kalari, Krishna R. , Yuan, Jian , Boughey, Judy C. , Goetz, Matthew P. , Sarkaria, Jann N. , Lou, Zhenkun

Mayo Clinic

Molecular Cancer Therapeutics | August 30, 2018 | Volume: 17 | Issue: 11 | Pages: 2462-2472

10.1158/1535-7163.mct-18-0470 | PMID 30166399 Get It

Abstract Triple-negative breast cancer (TNBC) is characterized by elevated locoregional recurrence risk despite aggressive local therapies. New tumor-specific radiosensitizers are needed. We hypothesized that the ATR inhibitor, VX-970 (now known as M6620), would preferentially radiosensitize TNBC. Noncancerous breast epithelial and TNBC cell lines were investigated in clonogenic survival, cell cycle, and DNA damage signaling and repair assays. In addition, patient-derived xenograft (PDX) models generated prospectively as part of a neoadjuvant chemotherapy study from either baseline tumor biopsies or surgical specimens with chemoresistant residual disease were assessed for sensitivity to fractionated radiotherapy, VX-970, or the combination. To explore potential response biomarkers, exome sequencing was assessed for germline and/or somatic alterations in homologous recombination (HR) genes and other alterations associated with ATR inhibitor sensitivity. VX-970 preferentially inhibited ATR-Chk1-CDC25a signaling, abrogated the radiotherapy-induced G2–M checkpoint, delayed resolution of DNA double-strand breaks, and reduced colony formation after radiotherapy in TNBC cells relative to normal-like breast epithelial cells. In vivo, VX-970 did not exhibit significant single-agent activity at the dose administered even in the context of genomic alterations predictive of ATR inhibitor responsiveness, but significantly sensitized TNBC PDXs to radiotherapy. Exome sequencing and functional testing demonstrated that combination therapy was effective in both HR-proficient and -deficient models. PDXs established from patients with chemoresistant TNBC were also highly radiosensitized. In conclusion, VX-970 is a tumor-specific radiosensitizer for TNBC. Patients with residual TNBC after neoadjuvant chemotherapy, a subset at particularly high risk of relapse, may be ideally suited for this treatment intensification strategy. Mol Cancer Ther; 17(11); 2462–72. ©2018 AACR.